Mylan NV, of Hertfordshire, U.K., and Biocon Ltd., of Bangalore, India, said results of the HERITAGE study, published in the Journal of the American Medical Association, confirm the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon, in comparison to branded trastuzumab (Herceptin, Roche Holding AG).